You are here
Multicenter Study Validates SelectMDx's High Negative Predictive Value and Sensitivity for Prostate Cancer
IRVINE, Calif. and HERSTAL, Belgium, June 10, 2019 /PRNewswire/ -- MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative molecular diagnostics company, today announced positive data, published in The Journal of Urology, from a second clinical validation study of its liquid biopsy test SelectMDx for Prostate Cancer.
SelectMDx is a non-invasive urine test that measures the expression of two mRNA cancer-related biomarkers and provides results to help physicians determine whether a patient may benefit from a biopsy and early prostate detection or avoid a biopsy and return to routine screening. These new data support that SelectMDx may help physicians determine which patients are at risk of aggressive prostate cancer and help guide initial prostate biopsy decisions.
"The publication of these compelling data clearly demonstrates the clinical validity and value proposition of our SelectMDx test," said Michael McGarrity, CEO of MDxHealth. "We look forward to the continued progress on the adoption and coverage of our SelectMDx test in both the United States and in Europe."
Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer Prior to Initial Prostate Biopsy
Summary: In a clinical study of 1,955 men undergoing initial prostate biopsies, SelectMDx yielded a 95% negative predictive value and 93% sensitivity for the detection of clinically significant prostate cancer.
The full paper is accessible here via The Journal of Urology.
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of therapeutic response. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com.
For more information:
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx, PredictMDx and UrNCollect are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.
View original content to download multimedia:http://www.prnewswire.com/news-releases/multicenter-study-validates-selectmdxs-high-negative-predictive-value-and-sensitivity-for-prostate-cancer-300864354.html